Last reviewed 2026-04-20 · How we verify

COLISTIN SULFATE

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Allergic contact dermatitis
• Itching
• Burning
• Irritation
• Dryness
• Folliculitis
• Hypertrichosis
• Acneiform eruptions
• Hypopigmentation
• Perioral dermatitis
• Maceration of the skin
• Secondary infection

Serious adverse events

• Ototoxicity
• Nephrotoxicity

Key clinical trials

• Phenotypic and Genotypic Detection of Colistin Resistance
• A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
• A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
• Effect of Diluent Volume on Colistin Inhalation Therapy (NA)
• Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia (PHASE2, PHASE3)
• Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity (PHASE2, PHASE3)
• Therapeutic Options for CRAB (PHASE4)
• Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• COLISTIN SULFATE CI brief — competitive landscape report
• COLISTIN SULFATE updates RSS · CI watch RSS